Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-03-13
2009-11-24
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S365000, C548S146000
Reexamination Certificate
active
07622472
ABSTRACT:
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
REFERENCES:
patent: 6596746 (2003-07-01), Das et al.
patent: 2004/0024208 (2004-02-01), Das et al.
patent: 2004/0054186 (2004-03-01), Das et al.
patent: 2004/0057950 (2004-03-01), Waksal et al.
patent: 2004/0073026 (2004-04-01), Das et al.
patent: 2004/0077875 (2004-04-01), Das et al.
patent: 2004/0209930 (2004-10-01), Carboni et al.
patent: 2005/0215795 (2005-09-01), Chen et al.
patent: WO00/62778 (2000-10-01), None
patent: WO03/013540 (2003-02-01), None
patent: WO2004/085388 (2004-10-01), None
patent: WO2005/076990 (2005-08-01), None
Golas et al., “SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases. Is a Potent Antiproliferative Agent Against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice,”Cancer Research, vol. 63, pp. 375-381, 2003.
Office Action and Response by applicant dated Apr. 8, 2005 for U.S. Appl. No. 10/378,373.
Office Action U.S. Appl. No. 11/271,626.
Bristol--Myers Squibb Company
Gembeh Shirley V
Hartley Michael G
VanAtten Mary K.
LandOfFree
Combination of Src kinase inhibitors and chemotherapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of Src kinase inhibitors and chemotherapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of Src kinase inhibitors and chemotherapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4120784